H.C. Wainwright maintains AnaptysBio stock Neutral rating, $19 target
AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Analyst Expectations For AnaptysBio's Future
Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...
GlobalData on MSN2d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...
Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But ...
AnaptysBio’s (ANAB) Neutral Rating Reiterated at HC Wainwright
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $19.00 ...
Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)
Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the ...
AnaptysBio initiated with an Outperform at Wolfe Research
Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...
Yahoo Finance4d
AnaptysBio, Inc. (ANAB)
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...
Contract Pharma3d
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
H.C. Wainwright维持AnaptysBio股票中性评级，目标价19美元
周二，H.C. Wainwright维持AnaptysBio (NASDAQ: ANAB )的中性评级和19.00美元的目标价。根据InvestingPro数据，该股目前交易价格为16.66美元，今年以来上涨25.8%，但过去六个月大幅下跌49%，显示出显著的波动性。该公司分析师Emily Bodnar对AnaptysBio最近与Vanda ...